Clinical Pharmacology of Antitubercular Drugs (Q40145554)

17 September 2017

1 reference

title

Clinical pharmacology of antitubercular drugs (English)

1 reference

17 September 2017

Clinical Pharmacology of Antitubercular Drugs (English)

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

2 October 2023

1 reference

2

Blumer JL

1 reference

17 September 2017

M. D. Reed

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6338464

2 October 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6338464

2 October 2023

publication date

1 February 1983

1 reference

full work available at URL

17 September 2017

https://api.elsevier.com/content/article/PII:S0031395516343280?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

https://api.elsevier.com/content/article/PII:S0031395516343280?httpAccept=text/plain

2 October 2023

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Pediatric Clinics of North America

2 October 2023

published in

1 reference

17 September 2017

volume

30

1 reference

17 September 2017

issue

1

1 reference

17 September 2017

page(s)

177-193

1 reference

Clinical Pharmacokinetics of Rifampicin

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

The Side Effects and Interactions of Antituberculosis Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Uptake and binding of 14C-ethambutol by tubercle bacilli and the relation of binding to growth inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Chemical Characterization of Ethambutol Binding to Mycobacterium smegmatis

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Rifampicin and methadone withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Guidelines for drug therapy in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Effects of isoniazid on pyridoxine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Rifampicin-induced immune thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Ethambutol in Tuberculous Meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Letter: Rifampicin and oral contraception.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Stevens-Johnson syndrome caused by isoniazid

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Effect of rifampicin on liver function in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Hepatotoxicity of rifampicin and isoniazid in children

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Rifamycin antibiotics in chronic purulent bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

The susceptibility of mycobacteria to rifamide and rifampicin.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Isoniazid plus ethambutol in the initial treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Acute renal failure after rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Febrile reactions to INH

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Specificity of Isoniazid on Growth Inhibition and Competition for an Oxidized Nicotinamide Adenine Dinucleotide Regulatory Site on the Electron Transport Pathway in Mycobacterium phlei

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Cerebrospinal Fluid Concentrations of Rifampin in Meningeal Tuberculosis1,2

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Short-course Chemotherapy for Tuberculosis with Largely Twice-weekly Isoniazid-Rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Tuberculosis Due to Mycobacterium Kansasii

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Absorption, metabolism and excretion of pyrazinamide in man

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Acute renal failure and rifampicin: danger of unsuspected intermittent dosage.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Effect of ethambutol on Mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Pyrazinamide and other drugs in tuberculous meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Side effects of intermittent rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Adverse reactions to rifampicin in antituberculosis regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Isoniazid: a review with emphasis on adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Rheumatic symptoms during tuberculosis therapy. A manifestation of isoniazid toxicity?

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Suppression of T-lymphocyte rosettes by rifampin. Studies in normals and patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Current concepts of the metabolism of antituberculous agents

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Rifampin, a Powerful New Antimicrobial Agent

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea-pig hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Hypersensitivity to anti-tuberculous drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Acute renal failure after rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Antibiotics and the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Rifampin-Induced Methadone Withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Depression of parahydroxylation of diphenylhydantoin by antituberculosis chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Effect of Rifampicin and Isoniazid on Liver Function

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Eidotorial: Antituberculous drugs and the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Jaundice after rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Toxicity form rifampicin plus isoniazid and rifampicin plus ethambutol therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

The ocular toxicity of ethambutol and its relation to dose

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Treatment of Experimental Staphylococcal Infection with Rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Killing of Intraleukocytie Staphylococcus aureus by Rifampin: In-Vitro and In-Vivo Studies

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Effect of para-aminosalicylic acid on serum isoniazid levels in man

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Interaction of sodium warfarin and rifampin. Studies in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Interaction of chronic daily warfarin therapy and rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

THE ABSORPTION, EXCRETION, AND METABOLIC FATE OF ETHAMBUTOL IN MAN

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Acute Arthritis Induced by Isoniazid

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Potentially Serious Side Effects of High-dose Twice-weekly Rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Hyperuricemia Due to Ethambutol

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Sensitivity to rifampicin: incidence, mechanism, and prevention.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Toxicologic and pharmacologic aspects of rifampin.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Practical management and control of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Hemolytic anemia with positive Coombs' test. Association with isoniazid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Isoniazid induction of antinuclear antibodies. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Hepatorenal failure with self-initiated intermittent rifampicin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

1 reference

7 January 2021

Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Rifampicin hepatitis. A clinical and histological study

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Rifampin, oral contraceptives, and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Isoniazid liver injury during chemoprophylaxis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Acute diffuse interstitial nephritis related to chemotherapy of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Bacterial cell wall synthesis and structure in relation to the mechanism of action of penicillins and other antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Letter: Rifampicin and drug metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

The effect of rifampicin on liver morphology in tuberculous alcoholics

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

The Role of Metabolism in the Hepatotoxicity of Isoniazid and Iproniazid

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Peripheral neuropathy with ethambutol

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Fatal hepatic necrosis due to isoniazid chemoprophylaxis in a 15-year-old girl

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Isoniazid distribution in body fluids of the dog and the rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Susceptibility of Mycobacteria to Rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Letter: Induction of hepatic cortisol-6-hydroxylase by rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2816%2934328-0

7 January 2021

Isoniazid-associated hepatitis

4

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Drugs for treatment of tuberculosis

2 October 2023

5

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

The in vitro action of cycloserine on M. tuberculosis

2 October 2023

8

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Lung infection with anonymous mycobacteria

2 October 2023

10

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Liver enzyme disturbances during isoniazid chemoprophylaxis in children

2 October 2023

11

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

The hepatic toxicity of isoniazid among rapid and slow acetylators of the drug

2 October 2023

42

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

On the metabolic fate of isoniazid

2 October 2023

60

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Effects of antacids on gastrointestinal absorption of isoniazid in rat and man

2 October 2023

61

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol, and rifampin

2 October 2023

64

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

2 October 2023

71

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Isoniazid acetylation rates (phenotypes) of patients being treated for tuberculosis

2 October 2023

88

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Control study of biologically active isoniazid in serum of children with primary tuberculosis

2 October 2023

94

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Clinical pharmacology of ethambutol

2 October 2023

104

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Hepatitis cases in isoniazid treated groups and in a control group

2 October 2023

113

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Hepatic complications of antituberculous therapy

2 October 2023

116

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Isoniazid administration and liver injury

2 October 2023

120

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Intermittent chemotherapy for adults with tuberculosis

2 October 2023

122

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Long-term effectiveness of intermittent therapy for tuberculosis: final report of three Denver studies

2 October 2023

123

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Chemical modifications and biological properties of rifamycins

2 October 2023

126

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Rifampin concentrations in cerebrospinal fluid of patients with tuberculous meningitis

2 October 2023

129

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Tuberculosis and other mycobacterial infections

2 October 2023

131

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

A current appraisal of cycloserine

2 October 2023

137

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Antituberculosis agents: isoniazid, rifampin, streptomycin, ethambutol

2 October 2023

150

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention

2 October 2023

153

1 reference

https://api.crossref.org/works/10.1016/S0031-3955(16)34328-0

2 October 2023

Identifiers

0 references

1 reference